Search This Blog

Thursday, March 14, 2019

Spero Therapeutics reports Q4 EPS (60c), consensus (75c)

Reports Q4 grant revenue $1.69M, consensus $760,000.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)